3.28
0.15 (4.79%)
| 前收盘价格 | 3.13 |
| 收盘价格 | 3.00 |
| 成交量 | 14,984 |
| 平均成交量 (3个月) | 31,304 |
| 市值 | 35,314,448 |
| 价格/销量 (P/S) | 0.410 |
| 股市价格/股市净资产 (P/B) | 0.370 |
| 52周波幅 | |
| 利润日期 | 26 May 2025 - 30 May 2025 |
| 营业毛利率 | -67.20% |
| 营业利益率 (TTM) | -37.14% |
| 稀释每股收益 (EPS TTM) | -4.62 |
| 季度收入增长率 (YOY) | 4.10% |
| 总债务/股东权益 (D/E MRQ) | 9.01% |
| 流动比率 (MRQ) | 2.92 |
| 营业现金流 (OCF TTM) | -92.26 M |
| 杠杆自由现金流 (LFCF TTM) | -60.07 M |
| 资产报酬率 (ROA TTM) | -20.93% |
| 股东权益报酬率 (ROE TTM) | -51.38% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看跌 | 看跌 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | Burning Rock Biotech Limited | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.13 |
|
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 内部持股比例 | 0.04% |
| 机构持股比例 | 64.35% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Crcm Lp | 31 Dec 2024 | 325,969 |
| Shen Neil Nanpeng | 31 Dec 2024 | 885 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 25 Mar 2025 | 公告 | Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合